야간뇨 환자에서 cyclooxygenase-2 억제제의 임상적 효과
Clinical Effects of Cycloxygenase-2 Inhibitor on Nocturia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to examine the effects of cyclooxgenase-2 inhibitors on patients with nocturia, whose symptoms persisted after the use of first-line drug therapy, such as alpha blockers and/or anticholinergics. Materials and Methods: Thirty-three patients whose symptoms persisted after more than three months of first-line drug therapy were chosen to receive additional COX-2 inhibitors or antidiuretic hormones orally. Seven patients (group 1) were given 80mg of zaltoprofen at night, while 15 (group 2) were given 100mg of nimesulide at night. Desmopressin acetate (0.2mg) was administered at night to 11 patients (group 3) as a control group. Median follow up was 35 days (range, 28∼90 days). Results: In 25 patients (75.8%), the severity of nocturia was reduced. The median decline of nocturia in the COX-2 inhibitor groups (groups 1 and 2) was once, and it was statistically significant (p<0.001), while the median decline in each of these groups was twice (p=0.026) and once (p=0.002), respectively. The reduction of nocturia in the control group was once (p=0.011). The differences in reduction between the COX-2 inhibitor group and the control group were not statistically significant (p=0.418). Conclusions: The effects of the COX-2 inhibitors were not significantly different from those of desmopressin. Combination therapy with COX-2 inhibitors can effectively reduce nocturia in patients with refractory nocturia, following first-line drug therapy. (J Korean Continence Soc 2009;13:67-72)
Abstract
Purpose: This study aimed to examine the effects of cyclooxgenase-2 inhibitors on patients with nocturia, whose symptoms persisted after the use of first-line drug therapy, such as alpha blockers and/or anticholinergics. Materials and Methods: Thirty-three patients whose symptoms persisted after more than three months of first-line drug therapy were chosen to receive additional COX-2 inhibitors or antidiuretic hormones orally. Seven patients (group 1) were given 80mg of zaltoprofen at night, while 15 (group 2) were given 100mg of nimesulide at night. Desmopressin acetate (0.2mg) was administered at night to 11 patients (group 3) as a control group. Median follow up was 35 days (range, 28∼90 days). Results: In 25 patients (75.8%), the severity of nocturia was reduced. The median decline of nocturia in the COX-2 inhibitor groups (groups 1 and 2) was once, and it was statistically significant (p<0.001), while the median decline in each of these groups was twice (p=0.026) and once (p=0.002), respectively. The reduction of nocturia in the control group was once (p=0.011). The differences in reduction between the COX-2 inhibitor group and the control group were not statistically significant (p=0.418). Conclusions: The effects of the COX-2 inhibitors were not significantly different from those of desmopressin. Combination therapy with COX-2 inhibitors can effectively reduce nocturia in patients with refractory nocturia, following first-line drug therapy. (J Korean Continence Soc 2009;13:67-72)
참고문헌 (17)
- Hilton P, "The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female", Br J Urol, 54, pp.252~255 (1982)
- Stewart RB, "Nocturia: a risk factor for falls in the elderly", J Am Geriatr Soc, 40, pp.1217~1220 (1992)
- Araki T, "Effectiveness of a nonsteroidal anti-inflammatory drugs for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60mg once daily before sleeping", Acta Med, 58, pp.45~49 (2004)
- Weiss JP, "Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices", Neurourol Urodyn, 18, pp.559~565 (1999)
- Rewsnick NM, "Geriatric incontinence and voiding dysfunction. In: Campbell’s Urology, 8th edn", pp.1224~1225 (2002), WB Saunders
- Johnson TM, "Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of Veterans Affairs Cooperative Study Trial", J Urol, 170, pp.145~148 (2003)
- Bruskewitz RC, "3-year followup of urinary symptoms after transurethral resection of the prostate", J Urol, 136, pp.613~615 (1986)
- Wasson JH, "A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostate hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate", N Engl J Med, 332, pp.75~79 (1995)
- 장혁수, "야간뇨를 호소하는 전립선비대증 환자에서 Loxoprofen Sodium의 효과", Korean Journal of Urology, 48(2), pp.195~198 (2007), 대한비뇨기과학회
- Al-Waili NS, "Increased urinary nitrite excretion in primary enuresis: effects of indomethacin treatment on urinaryand serum osmolality and electrolytes, urinary volumes and nitrite excretion", BJU Int, 90, pp.294~301 (2002)
- Al-Waili NS, "indomethacin suppository to treat primary nocturnal enuresis: double-blind crossover study", J Urol, 142, pp.1290~1292 (1989)
- Addla SK, "Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study", European urology, 49, pp.720~726 (2006)
- van Kerrebroeck P, "Desmopressin in the Treatment of Nocturia: A Double Blind, Placebo-Controlled Study", Eur Urol, 52(1), pp.221~229 (2007)
- 남상간, "성인 야간뇨 환자에서 항이뇨호르몬제의 효과", Korean Journal of Urology, 45(1), pp.49~55 (2004), 대한비뇨기과학회
- Schussler B, "Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. a urodynamic study", Urol Res, 18, pp.349~352 (1990)
- Mitchell JA, "Cyclooxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy", Br J Pharmacol, 124, pp.865~872 (1998)
- Yokoyama O, "Overactive bladder-experimental aspects", Scand J Urol Nephrol, 210, pp.59~64 (2002)